Elevated BAFF levels are detected in human patients with SLE; therefore, targeting the BAFF/receptor axis has emerged as a logical therapeutic candidate for control of SLE through the modulation of aberrant autoantibody production by autoreactive B cells20–22. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.